Physician profile
Eric S Applebaum
NPI 1336137272
$1,497.82
in general payments reported to CMS, 2019-2025
11 companies · $247 in 2025
The $247 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $111 · 2021: $77.22 · 2022: $232 · 2023: $317 · 2024: $306 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $869.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $823.49 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $168.00 | 2021-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Kaleo, INC. | $113.07 | 2020-2023 | Auvi-Q |
| Alexion Pharmaceuticals, INC. | $111.64 | 2024 | |
| Covis Pharma Gmbh | $98.21 | 2019-2022 | |
| Optinose US, INC. | $74.57 | 2022-2025 | |
| Alk-Abello, INC | $29.21 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $27.68 | 2020 | |
| Genzyme Corporation | $25.96 | 2022 | |
| Mylan Specialty L.P. | $13.28 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Applebaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.